Chronic olanzapine administration in rats: Effect of route of administration on weight, food intake and body composition

Pharmacology Biochemistry and Behavior

Volumn 103, Issue 4, 2013, Pages 717-722

  Mann, Steve ^a   Chintoh, Araba ^b   Giacca, Adria ^b   Fletcher, Paul ^b   Nobrega, Jose ^b   Hahn, Margaret ^a,b   Remington, Gary ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Animal models; Drug formulation; Olanzapine; Weight gain

Indexed keywords

OLANZAPINE; PLACEBO;

ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOOD INTAKE; INTRAABDOMINAL FAT; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY COMPOSITION; BODY WEIGHT; EATING; FEMALE; INFUSION PUMPS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84873396837     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2012.12.002     Document Type: Article

References (78)

1. W. Aichhorn, A.B. Whitworth, E.M. Weiss, and J. Marksteiner Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 29 2006 587 598
2. V.L. Albaugh, C.R. Henry, N.T. Bello, A. Hajnal, S.L. Lynch, and B. Halle Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents Obesity (Silver Spring) 14 2006 36 51
3. D.B. Allison, and D.E. Casey Antipsychotic-induced weight gain: a review of the literature J Clin Psychiatry 62 Suppl. 7 2001 22 31
4. M. Aravagiri, Y. Teper, and S.R. Marder Pharmacokinetics and tissue distribution of olanzapine in rats Biopharm Drug Dispos 20 1999 369 377
5. T. Baptista Mechanisms of weight gain induced by antipsychotic drugs J Clin Psychiatry 63 2002 245 246
6. T. Baptista, M. Parada, and L. Hernandez Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27 1987 399 405
7. T. Baptista, E. Araujo de Baptista, N.M. Ying Kin, S. Beaulieu, D. Walker, and R. Joober Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance Brain Res 957 2002 144 151
8. T. Baptista, A. Lacruz, X. Paez, L. Hernandez, and S. Beaulieu The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur J Pharmacol 447 2002 91 98
9. T. Baptista, E.A. de Baptista, J. Lalonde, J. Plamondon, N.M. Kin, and S. Beaulieu Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection Prog Neuropsychopharmacol Biol Psychiatry 28 2004 1305 1311
10. T. Baptista, S. De Mendoza, S. Beaulieu, A. Bermudez, and M. Martinez The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management Metab Syndr Relat Disord 2 2004 290 307
11. B.R. Basson, B.J. Kinon, C.C. Taylor, K.A. Szymanski, J.A. Gilmore, and G.D. Tollefson Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone J Clin Psychiatry 62 2001 231 238
12. H.N. Boyda, L. Tse, R.M. Procyshyn, W.G. Honer, and A.M. Barr Preclinical models of antipsychotic drug-induced metabolic side effects Trends Pharmacol Sci 31 2010 484 497
13. H.N. Boyda, R.M. Procyshyn, L. Tse, D. Wong, C.C. Pang, and W.G. Honer Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats Neuropharmacology 62 2012 1391 1400
14. J.T. Callaghan, R.F. Bergstrom, L.R. Ptak, and C.M. Beasley Olanzapine. Pharmacokinetic and pharmacodynamic profile Clin Pharmacokinet 37 1999 177 193
15. A.F. Chintoh, S.W. Mann, L. Lam, C. Lam, T.A. Cohn, and P.J. Fletcher Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration J Clin Psychopharmacol 28 2008 494 499
16. A.F. Chintoh, S.W. Mann, T.K. Lam, A. Giacca, and G. Remington Insulin resistance following continuous, chronic olanzapine treatment: an animal model Schizophr Res 104 2008 23 30
17. A.F. Chintoh, S.W. Mann, L. Lam, A. Giacca, P. Fletcher, and J. Nobrega Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model Schizophr Res 108 2009 127 133
18. J.A. Chiu, and R.B. Franklin Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection J Pharm Biomed Anal 14 1996 609 615
19. S. Choi, B. DiSilvio, J. Unangst, and J.D. Fernstrom Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats Life Sci 81 2007 1024 1030
20. L. Citrome, A. Jaffe, J. Levine, and D. Martello Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004 Psychiatr Serv 57 2006 1132 1139
21. L. Citrome, V.L. Stauffer, L. Chen, B.J. Kinon, D.L. Kurtz, and J.G. Jacobson Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration J Clin Psychopharmacol 29 2009 278 283
22. T. Cohn, D. Prud'homme, D. Streiner, H. Kameh, and G. Remington Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome Can J Psychiatry 49 2004 753 760
23. T.A. Cohn, G. Remington, R.B. Zipursky, A. Azad, P. Connolly, and T.M. Wolever Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report Can J Psychiatry 51 2006 382 386
24. G.D. Cooper, L.C. Pickavance, J.P. Wilding, J.C. Halford, and A.J. Goudie A parametric analysis of olanzapine-induced weight gain in female rats Psychopharmacology (Berl) 181 2005 80 89
25. G.D. Cooper, L.C. Pickavance, J.P. Wilding, J.A. Harrold, J.C. Halford, and A.J. Goudie Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities J Psychopharmacol 21 2007 405 413
26. G.D. Cooper, J.A. Harrold, J.C. Halford, and A.J. Goudie Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain Prog Neuropsychopharmacol Biol Psychiatry 32 2008 428 436
27. U. Eder, B. Mangweth, C. Ebenbichler, E. Weiss, A. Hofer, and M. Hummer Association of olanzapine-induced weight gain with an increase in body fat Am J Psychiatry 158 2001 1719 1722
28. M.J. Fell, K.M. Marshall, J. Williams, and J.C. Neill Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats J Psychopharmacol 18 2004 149 155
29. M.J. Fell, J.C. Neill, C. Rao, and K.M. Marshall Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats Psychopharmacology (Berl) 182 2005 499 507
30. M.J. Fell, N. Anjum, K. Dickinson, K.M. Marshall, L.M. Peltola, and S. Vickers The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats Psychopharmacology (Berl) 194 2007 221 231
31. M.J. Fell, J.C. Neill, N. Anjum, L.M. Peltola, and K.M. Marshall Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats J Psychopharmacol 22 2008 182 186
32. M.A. Geyer, and B. Ellenbroek Animal behavior models of the mechanisms underlying antipsychotic atypicality Prog Neuropsychopharmacol Biol Psychiatry 27 2003 1071 1079
33. M. Gilles, F. Hentschel, G. Paslakis, V. Glahn, F. Lederbogen, and M. Deuschle Visceral and subcutaneous fat in patients treated with olanzapine: a case series Clin Neuropharmacol 33 2010 248 249
34. A.J. Goudie, J.A. Smith, and J.C. Halford Characterization of olanzapine-induced weight gain in rats J Psychopharmacol 16 2002 291 296
35. M. Hahn, A. Chintoh, A. Giacca, L. Xu, L. Lam, and S. Mann Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model Schizophr Res 131 2011 90 95
36. A.W. Hartfield, N.A. Moore, and P.G. Clifton Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat Psychopharmacology (Berl) 167 2003 115 122
37. D.C. Henderson Weight gain with atypical antipsychotics: evidence and insights J Clin Psychiatry 68 Suppl. 12 2007 18 26
38. D.C. Henderson, E. Cagliero, P.M. Copeland, C.P. Borba, E. Evins, and D. Hayden Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis Arch Gen Psychiatry 62 2005 19 28
39. S.A. Hollingworth, D.J. Siskind, L.M. Nissen, M. Robinson, and W.D. Hall Patterns of antipsychotic medication use in Australia 2002-2007 Aust N Z J Psychiatry 44 2010 372 377
40. K.L. Houseknecht, A.S. Robertson, W. Zavadoski, E.M. Gibbs, D.E. Johnson, and H. Rollema Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects Neuropsychopharmacology 32 2007 289 297
41. J.I. Javaid Clinical pharmacokinetics of antipsychotics J Clin Pharmacol 34 1994 286 295
42. D.V. Jeste, B.W. Palmer, and M.J. Harris Neuroleptic discontinuation in clinical and research settings: scientific issues and ethical dilemmas Biol Psychiatry 46 1999 1050 1059
43. M. Kalinichev, C. Rourke, A.J. Daniels, M.K. Grizzle, C.S. Britt, and D.M. Ignar Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats Psychopharmacology (Berl) 182 2005 220 231
44. M. Kalinichev, C. Rourke, and D.N. Jones Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine Behav Pharmacol 17 2006 289 292
45. S. Kapur, and G. Remington Serotonin-dopamine interaction and its relevance to schizophrenia Am J Psychiatry 153 1996 466 476
46. S. Kapur, and G. Remington Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient Biol Psychiatry 50 2001 873 883
47. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy J Pharmacol Exp Ther 305 2003 625 631
48. K. Kassahun, E. Mattiuz, E. Nyhart Jr., B. Obermeyer, T. Gillespie, and A. Murphy Disposition and biotransformation of the antipsychotic agent olanzapine in humans Drug Metab Dispos 25 1997 81 93
49. B.J. Kinon, I. Lipkovich, S.B. Edwards, D.H. Adams, H. Ascher-Svanum, and S.G. Siris A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms J Clin Psychopharmacol 26 2006 157 162
50. B. Kirkpatrick, B.J. Miller, C. Garcia-Rizo, E. Fernandez-Egea, and M. Bernardo Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull 38 2012 280 284
51. D. Kohen Diabetes mellitus and schizophrenia: historical perspective Br J Psychiatry Suppl 47 2004 S64 S66
52. S.K. Kulkarni, and A. Dhir Animal models of tardive dyskinesia Int Rev Neurobiol 98 2011 265 287
53. M.D. Lee, and P.G. Clifton Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol Pharmacol Biochem Behav 71 2002 147 154
54. Y.K. Luu, S. Lublinsky, E. Ozcivici, E. Capilla, J.E. Pessin, and C.T. Rubin In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model Med Eng Phys 31 2009 34 41
55. A. Matsui-Sakata, H. Ohtani, and Y. Sawada Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus Drug Metab Pharmacokinet 20 2005 368 378
56. J. Minet-Ringuet, P.C. Even, B. Guesdon, D. Tome, and R. de Beaurepaire Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection Behav Brain Res 163 2005 204 211
57. J. Minet-Ringuet, P.C. Even, M. Goubern, D. Tome, and R. de Beaurepaire Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration Appetite 46 2006 254 262
58. J. Minet-Ringuet, P.C. Even, M. Lacroix, D. Tome, and R. de Beaurepaire A model for antipsychotic-induced obesity in the male rat Psychopharmacology (Berl) 187 2006 447 454
59. D.J. Muller, and J.L. Kennedy Genetics of antipsychotic treatment emergent weight gain in schizophrenia Pharmacogenomics 7 2006 863 887
60. J.W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 Suppl. 1 2005 1 93
61. J.W. Newcomer Metabolic considerations in the use of antipsychotic medications: a review of recent evidence J Clin Psychiatry 68 Suppl. 1 2007 20 27
62. B. Parsons, D.B. Allison, A. Loebel, K. Williams, E. Giller, and S. Romano Weight effects associated with antipsychotics: a comprehensive database analysis Schizophr Res 110 2009 103 110
63. B.M. Patil, N.M. Kulkarni, and B.S. Unger Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain Eur J Pharmacol 551 2006 112 115
64. B. Pouzet, T. Mow, M. Kreilgaard, and S. Velschow Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human Pharmacol Biochem Behav 75 2003 133 140
65. K. Ramaswamy, P.S. Masand, and H.A. Nasrallah Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies Ann Clin Psychiatry 18 2006 183 194
66. M.A. Raskind, B.L. Burke, N.J. Crites, A.M. Tapp, and D.D. Rasmussen Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats Neuropsychopharmacology 32 2007 284 288
67. C. Reist, J. Mintz, L.J. Albers, M.M. Jamal, S. Szabo, and V. Ozdemir Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002 J Clin Psychopharmacol 27 2007 46 51
68. G. Remington Understanding antipsychotic "atypicality": a clinical and pharmacological moving target J Psychiatry Neurosci 28 2003 275 284
69. G. Remington From mice to men: what can animal models tell us about mental health and physical activity? Ment Health Phys Act 2 2009 10 15
70. G. Remington, S. Mann, P. McCormick, J.N. Nobrega, M. Hahn, and S. Natesan Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations Pharmacol Biochem Behav 100 2011 86 89
71. M.C. Ryan, P. Collins, and J.H. Thakore Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia Am J Psychiatry 160 2003 284 289
72. G.S. Sachs, and C. Guille Weight gain associated with use of psychotropic medications J Clin Psychiatry 60 Suppl. 21 1999 16 19
73. M. Shobo, H. Yamada, A. Koakutsu, N. Hamada, M. Fujii, and K. Harada Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats Life Sci 88 2011 761 765
74. L.M. Spelman, P.I. Walsh, N. Sharifi, P. Collins, and J.H. Thakore Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia Diabet Med 24 2007 481 485
75. E.M. van der Zwaal, M.C. Luijendijk, R.A. Adan, and S.E. la Fleur Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution Eur J Pharmacol 585 2008 130 136
76. S. Weinbrenner, H.J. Assion, T. Stargardt, R. Busse, G. Juckel, and C.A. Gericke Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund Pharmacopsychiatry 42 2009 66 71
77. M. Yang, J.C. Barner, K.A. Lawson, K.L. Rascati, J.P. Wilson, and M.L. Crismon Antipsychotic medication utilization trends among Texas veterans: 1997-2002 Ann Pharmacother 42 2008 1229 1238
78. R.B. Zipursky, H. Gu, A.I. Green, D.O. Perkins, M.F. Tohen, and J.P. McEvoy Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol Br J Psychiatry 187 2005 537 543